Business Wire

NOVAMEDICA

Del
Omega Pharma and NovaMedica to market a line of gastrointestinal products under BenegastTM brand in Russia

Russian pharmaceutical company NovaMedica and Omega Pharma, a Belgium-based pan-European pharmaceutical company specializing in the development and sale of over-the-counter (OTC) health and personal care products, have signed a partnership agreement granting NovaMedica exclusive rights to promote, distribute and sell a line of OTC gastrointestinal products under the BenegastTM umbrella brand in Russia.

“Partnering with Omega Pharma is in line with NovaMedica’s strategy and our focus on delivering innovative treatments for gastrointestinal (GI) patients. The Benegast portfolio has strong synergies with NovaMedica’s current line of GI pharmaceutical products,” said Sergey Beloborodov, Executive Director of NovaMedica LLC. “Benegast products have been marketed successfully in Europe and are ready for fast-track launch in Russia. This is the first umbrella brand solution to address most common symptoms in gastroenterology, and we are confident of its commercial success.”

“We see the serious market potential for Benegast products in Russia, and we are glad that our partnership with NovaMedica will allow the Russian population to gain access to innovative GI products, to feel their efficacy and to improve quality of life,” noted Irina Moustiatsa, Country Manager of Omega Pharma in Russia.

NovaMedica plans to start marketing Benegast products in January 2015. NovaMedica intends to actively promote Benegast products to pharmacies throughout Russia, and will launch a national advertising campaign.

Key products in the portfolio include:

Benegast Reduflux , which contains the proprietary compound Phycodol that provides fast and sustainable relief from heartburn and indigestion. Phycodol, made of high quality extract from brown algae, forms a superior protective barrier on top of the stomach content to instantly suppress acid reflux while preventing pain and discomfort. Available in the form of peppermint flavored chewable tablets.

Benegast Redugas reduces bloating and restores healthy gut flora, thanks to its key ingredient Lycosyl, an effective combination of Simethicone and prebiotics (Inulin). Simethicone physically destroys gas bubbles, while prebiotics restore a healthy gut flora, thus reducing new gas build-up. Available in the form of peppermint-flavored chewable tablets.

Benegast Regulamine contains Chiasyll, a combination of two types of soluble and insoluble fibers to restore and maintain regularity. Chiasyll is the unique combination of Psyllium Husk with Chia Seed for a synergistic effect. Together the two types of fibers form a lubricating gel on the intestines to ease the transit and allow a stronger bulking effect to speed up transit time. These effects restore regularity and eliminate constipation. Available in the form of orange flavored powder in stick-sachets.

Additional information:

NovaMedica is a Russian pharmaceutical company established in 2012 by DRI Holdings Limited, a portfolio company of Domain Associates LLC, and Russian investment corporation RUSNANO, which implements government policy of fostering the development of hi-tech industries. The company’s strategy is aimed at localizing production of a wide range of new medicines and technologies in the Russian market, including screening and registration of new pharmaceuticals, and the creation of innovative GMP-standard manufacturing facilities. www.novamedica.com

Omega Pharma is an OTC healthcare company headquartered in Nazareth, Belgium with operations in 35 countries across Europe and select emerging markets. Its products are sold across an extensive network of pharmacies and related retail outlets. With over 2,500 employees, the Company generated sales of more than €1.2 billion in 2013, with more than half of these sales made by its top 20 brands. www.omega-pharma.com

Contact:

For NovaMedica
Tatyana Albaut, +7 917 545 1241
talbaut@team-drive.ru

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

New Murata Automotive-Compliant Chip Ferrite Beads Deliver Wide Band Noise Suppression of High-Frequency (5.9GHz) C-V2X19.6.2025 04:00:00 CEST | Press release

The new BLM15VM series is ideal for automotive powertrains and safety applications. It supports high frequencies. 1000Ω (Typ.) @5.9GHz. With its compact 0402-inch size (1.0×0.5mm) can operate at temperatures ranging from -55 to 150°C. And it is compliant with AEC-Q200. Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) continues to push the envelope in automotive noise suppression technology with another industry first. By leveraging proprietary material technology and optimized structural design, the company’s new BLM15VM series of automotive-compliant chip ferrite beads deliver wide-band noise suppression of high-frequency (5.9GHz) 5G vehicle-to-everything (5G-V2X) applications that exhibit high impedance. Mass production is scheduled to begin in July 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618511573/en/ [Murata Manufacturing Co., Ltd.] New Chip Ferrite Beads for Automotive In recent years, t

AV and UAS Denmark Establish Strategic Partnership to Advance Allied UAS Capabilities in Europe18.6.2025 22:30:00 CEST | Press release

AeroVironment, Inc. (“AV”) (NASDAQ: AVAV) today announced it has signed a Memorandum of Understanding (MOU) with Hans Christian Andersen Aiport in Odense, Denmark–home to the UAS Denmark Test Center–to explore joint utilization of the center’s expansive airspace and advanced test facilities. The agreement aims to leverage UAS Denmark’s strategic range and infrastructure to support AV’s uncrewed aircraft system (UAS) demonstration operations, mission training, and customer integration activities across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618380337/en/ JUMP 20 executes a seamless landing on a moving ship (Photo: AV) The collaboration is expected to enable joint research and development (R&D) initiatives and accelerate the growth of the UAS Denmark Test Center as a regional epicenter for advanced UAS innovation, evaluation, and operational readiness. "This MOU represents a significant milestone in expa

Stone Harbor Investment Partners Introduces Emerging Markets Climate Impact Debt Fund18.6.2025 22:05:00 CEST | Press release

Actively managed, sustainable UCITS fund targets emerging market countriesThis is a marketing communication. Stone Harbor Investment Partners, an investment manager of Virtus Investment Partners, Inc. (NYSE: VRTS), has launched the Stone Harbor Emerging Markets Climate Impact Debt (Bloomberg: STHEMDI) (the “Fund”), a UCITS fund classified as Article 9 under the Sustainable Finance Disclosure Regulation (SFDR) that addresses decarbonization efforts occurring in Emerging Markets (EM) while seeking to deliver attractive long-term total returns for investors. The Fund invests in sustainable debt issued with proceeds dedicated to environmental activities, assets, projects or expenditures, with social bonds also permissible, of EM corporate, sovereign, quasi-sovereign and supranational issuers in hard currency. The Fund, with a sustainable objective to promote the transition towards an environmentally and socially sustainable economy, seeks to outperform the J.P Morgan EM Credit Green, Socia

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma18.6.2025 21:39:00 CEST | Press release

- Monjuvi® (tafasitamab-cxix) in combination with rituximab and lenalidomide is the first FDA-approved CD19- and CD20-targeted immunotherapy combination for adult patients with follicular lymphoma (FL) - Patients with relapsed or refractory FL achieved significantly improved progression-free survival with Monjuvi in combination with rituximab and lenalidomide in the Phase 3 registration trial - This milestone represents the second approved indication for Monjuvi in the United States Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615896694/en/ MONJUVI logo "Patients living with relapsed or refr

Andersen Consulting fortsætter sin globale udvidelse med tilføjelsen af Azurian Consulting18.6.2025 19:49:00 CEST | Pressemeddelelse

Andersen Consulting styrker sine evner inden for virksomhedstransformation, teknologi og kunstig intelligens via en samarbejdsaftale med Azurian Consulting. Azurian Consulting, der blev grundlagt i 2012, tilbyder en omfattende række af tjenester, herunder transformation af digital strategi, databaseret strategi, optimering af forretningsprocesser og forandringsledelse. Med base i Latinamerika hjælper Azurian Consulting kunder inden for en bred vifte af brancher såsom finansverdenen, detailhandel, forbrugervarer og fremstillingsindustrien. "Samarbejdet med Andersen Consulting åbner døren til nye markeder, styrker vores evne til at hjælpe multinationale kunder og giver vores team adgang til globale ressourcer," udtaler Nicolás Dueñas, der er administrerende direktør for Azurian Consulting. "Det repræsenterer en stærk synergi, der giver os mulighed for at kombinere vores regionale indsigt med Andersen Consultings globale platform og dermed styrke vores evne til at levere integrerede og sa

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye